aibioUnited Therapeutics UTHR buyback news
Top story · Oct 22, 2026 · aibio.space
United Therapeutics authorizes another $2 billion share repurchase
The new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30.
- Ticker
- UTHR
- Listing
- NASDAQ, United States
- Next date
- Fourth quarter 2026
- Chief executive
- Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer
Desk view · Opinion · Updated Oct 22, 2026
United Therapeutics is buying back stock while it waits on two FDA filings
United Therapeutics has a shrinking-to-flat inhaled prostacyclin business, two filed applications backed by strong phase 3 data, and $3.80 billion of cash that it is steadily returning to shareholders. The Liquidia settlement removes a major legal threat and brings in $330.4 million. Whether the franchise decline outruns the 2027 approvals the CEO expects is the open question.
Read the full desk viewaibio.space Investor Rank · Opinion
8/10 Positive view
Two filings backed by strong phase 3 data and $3.80 billion of cash, set against core inhaled sales that are slipping, with revenue down 2%.
- Technology
- 2/2
- Odds
- 2/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 1/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Treprostinil franchise plus organ bets. Four treprostinil products and a once-daily oral follow-on, ralinepag, sit alongside a long-dated organ manufacturing program.
- Odds
- Strong data, filings under review. Ralinepag cut clinical worsening risk 55% (hazard ratio 0.45) and Nebulized Tyvaso added 130.1 mL of lung function in IPF; the rare-disease NDA-to-approval base rate is 93.6%.
- Balance sheet
- Large cash, heavy buybacks. $3.80 billion in cash and investments at June 30, an undrawn $2.5 billion revolver and a new $2.0 billion repurchase authorization.
- Main risk
- Core franchise erosion. Revenue is down 2% year over year and Nebulized Tyvaso fell 18% in Q2, with the company blaming competitive therapies.
- Watch next
- FDA actions and the Liquidia cash. The company expects potential approvals in 2027, and $185 million from Liquidia is due within 30 business days of Oct. 13.
Top news on United
- Financings
United Therapeutics authorizes another $2 billion share repurchase
The new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30.
- Legal
Liquidia settles all patent and trade secret litigation with United Therapeutics
The 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party.
- Distress
Liquidia to pay net $175 million in global settlement with United Therapeutics
The deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month.
Questions investors ask
What is aibio.space's Investor Rank for United Therapeutics?
8 out of 10, our positive view. Two filings backed by strong phase 3 data and $3.80 billion of cash, set against core inhaled sales that are slipping, with revenue down 2%. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
How much is Liquidia paying United Therapeutics in the settlement?
Liquidia agreed to pay United Therapeutics $330.4 million: $185 million within 30 business days of Oct. 13, 2026 and $145.4 million in two $72.7 million installments by Feb. 1 and April 30, 2027. United Therapeutics pays Liquidia $10.0 million to settle an antitrust case. Source
How big is United Therapeutics' new share buyback?
On Oct. 22, 2026 United Therapeutics announced a new share repurchase authorization of up to $2.0 billion, available through Oct. 21, 2027. An existing accelerated repurchase agreement from September is ongoing and does not reduce the new amount. Source
When could ralinepag be approved?
United Therapeutics submitted an NDA for ralinepag tablets in pulmonary arterial hypertension in June 2026. The CEO said on Aug. 5 that the company expects potential approvals for ralinepag and Nebulized Tyvaso in IPF next year; the filings do not state FDA action dates. Source
What were United Therapeutics' second-quarter 2026 results?
Revenue was $783.3 million, down 2% from $798.6 million a year earlier. Net income was $333.0 million, or $7.27 per diluted share. Tyvaso DPI sales rose 4% to $326.6 million while Nebulized Tyvaso fell 18% to $126.0 million. Source
How much cash does United Therapeutics have?
United Therapeutics held $3.80 billion in cash, cash equivalents and marketable investments at June 30, 2026, down from $4.70 billion at year-end 2025 after a $1.5 billion share repurchase. It had no balance outstanding on its $2.5 billion revolving credit facility. Source
What is the latest United Therapeutics (UTHR) stock news?
Our latest story on United Therapeutics, dated Oct 22, 2026: "United Therapeutics authorizes another $2 billion share repurchase". The new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30. Source
What is United Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Oct 22, 2026: "United Therapeutics authorizes another $2 billion share repurchase". The new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30. Source
What is United Therapeutics's market cap?
We do not publish live share prices. In its annual report, United Therapeutics Corporation put the market value of shares held by non-affiliates (public float) at $11.23 billion as of Jun 30, 2025. Source
Is United Therapeutics a smaller reporting company?
SEC records list United Therapeutics Corporation's filer category as: Large accelerated filer. Source
Where is United Therapeutics headquartered?
SEC records list its business address as 1000 SPRING ST, SILVER SPRING, MD, 20910. Source
When does United Therapeutics's fiscal year end?
United Therapeutics Corporation's fiscal year ends on December 31, per SEC records. Source
What did United Therapeutics last file with the SEC?
Its most recent filing in our record is an 8-K filed 2026-10-22. All of its filings are on SEC EDGAR. Source
What industry is United Therapeutics in?
Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source
Which other companies' news mentions United Therapeutics?
United Therapeutics is named in 2 of our stories about other companies, most recently: "Liquidia settles all patent and trade secret litigation with United Therapeutics" (Oct 14, 2026); "Liquidia to pay net $175 million in global settlement with United Therapeutics" (Oct 14, 2026). Source
Legal and investor matters
Part II, Item 1 of the 10-Q filed 2026-08-05 incorporates the Litigation note, which describes the Sandoz and MSP Recovery cases and, elsewhere in the filing, the Liquidia, Humana/United Healthcare and Boehringer matters. It does not mention a securities class action or shareholder derivative suit. This covers that filing only. Source
- Financing
United Therapeutics board approves $2.0 billion share repurchase program
United Therapeutics said in an 8-K that its board approved on October 21, 2026 a share repurchase program authorizing purchases of up to $2.0 billion of its common stock. The authorization remains in effect for a one-year period ending October 21, 2027. The company announced the program in a press release dated October 22, 2026, which it furnished as an exhibit to the filing.
- Litigation
United Therapeutics settles patent and trade secret litigation with Liquidia
United Therapeutics said in an 8-K that on October 13, 2026 it entered a settlement agreement with Liquidia Technologies resolving pending litigation, including a Delaware patent case in which the court held Liquidia liable for infringement on September 30, 2026. Liquidia will pay an aggregate of $330.4 million, including $185 million for past sales. Liquidia agreed to file to remove the PH-ILD indication from Yutrepia labeling. United Therapeutics will make a $10.0 million payment to Liquidia. The parties agreed to seek dismissal with prejudice of the actions, except that United Therapeutics may continue to pursue its trade secret claims against Dr. Roscigno.
- Financing
United Therapeutics enters $477.6 million accelerated share repurchase
United Therapeutics disclosed in an 8-K that on September 8, 2026 it entered into an accelerated share repurchase agreement with Citibank, N.A. to repurchase approximately $477.6 million of its common stock under its existing repurchase program. The company expected an initial delivery of approximately 719,376 shares. Final settlement is expected in the fourth quarter of 2026, and the final share count depends on volume-weighted average prices.
- Class action
Putative class action by MSP Recovery entities over charity donations remains pending
United Therapeutics reported in its 10-Q filed August 5, 2026 that in July 2020 MSP Recovery entities filed a class action complaint against Caring Voices Coalition and the company. The complaint alleges violations of the federal RICO Act and state laws. A magistrate judge recommended dismissal with prejudice on March 22, 2024, and the plaintiffs objected. The company says it intends to defend the case. This is not a securities class action.
- Litigation
Boehringer Ingelheim sues United Therapeutics in Delaware over sales hires
United Therapeutics reported in its 10-Q that on July 17, 2026 Boehringer Ingelheim Pharmaceuticals filed a complaint in the Delaware Court of Chancery. The complaint alleges misappropriation of trade secrets, aiding and abetting breaches of fiduciary duty and tortious interference in connection with the hiring of former Boehringer sales representatives. Boehringer seeks injunctive relief, damages and fees. The company says it has meritorious defenses and intends to defend the case.
- Financing
United Therapeutics sets $2.0 billion buyback and $1.5 billion accelerated repurchase
In an 8-K, United Therapeutics said its board approved a share repurchase program of up to $2.0 billion on March 8, 2026. On March 9, 2026 the company entered into two accelerated share repurchase agreements with Citibank, N.A. to repurchase approximately $1.5 billion of common stock. The agreements comprise a $750 million uncollared agreement and a $750 million collared agreement, with an upfront payment of $1.5 billion.
- Litigation
Humana and United Healthcare appeal dismissal of Maryland suits over charity donations
United Therapeutics reported in its 10-Q that Humana and United Healthcare each sued it in Maryland state court in April 2024, alleging that donations to Caring Voices Coalition violated state consumer protection and insurance fraud laws. The court dismissed both suits with prejudice on September 23, 2025. Humana and United each appealed on October 20, 2025, and the appeals to the Appellate Court of Maryland remain pending.
- Financing
United Therapeutics enters two accelerated share repurchases totaling about $1 billion
United Therapeutics said in an 8-K that its board approved a $1 billion share repurchase program, disclosed July 30, 2025. On August 1, 2025 the company entered into two accelerated share repurchase agreements with Citibank, N.A. to repurchase approximately $1 billion of common stock. The agreements are a $500 million uncollared agreement and a $500 million collared agreement, with an aggregate upfront payment of $1 billion on August 4, 2025.
- Financing
United Therapeutics enters $2.5 billion unsecured revolving credit agreement
United Therapeutics disclosed in an 8-K that on April 25, 2025 it entered into a Credit Agreement with Wells Fargo Bank, National Association as administrative agent. The agreement provides an unsecured revolving credit facility of up to $2.5 billion, which may be increased by up to $750 million subject to lender commitments. The facility matures five years after closing, subject to up to two one-year extensions at the lenders' election.
- Litigation
Court enters judgment against United Therapeutics in Sandoz contract case; appeal pending
United Therapeutics reported in its 10-Q that on November 1, 2024 the court entered final judgment for Sandoz in the case Sandoz and RareGen filed in New Jersey in April 2019, ordering it to pay about $61.6 million in damages and about $9.0 million in prejudgment interest. All parties appealed to the Third Circuit, which heard oral argument in November 2025, and the appeal was described as pending in the 10-Q. The company has accrued a liability reflecting the judgment.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Ralinepag extended-release tablets | Pulmonary arterial hypertension | NDA submitted June 2026 after positive phase 3 ADVANCE OUTCOMES (hazard ratio 0.45) Source |
| Nebulized Tyvaso (treprostinil) | Idiopathic pulmonary fibrosis (supplemental NDA) | sNDA submitted after positive TETON-1 and TETON-2; TETON-PPF phase 3 ongoing in progressive pulmonary fibrosis Source |
| Tyvaso DPI (treprostinil) | PH-ILD (marketed); IPF and PPF planned | Marketed; $326.6 million Q2 2026 sales Source |
| Treprostinil SMI | Pulmonary hypertension | NDA planned by end of 2026 Source |
| Ralinepag DPI | Pulmonary hypertension and fibrosis | IND planned by end of 2026 Source |
| Manufactured organs and xeno-organs | Liver, kidney, heart and lung organ replacement | Clinical trials ongoing or planned; two xeno-organ production facilities to launch later in 2026 Source |
Opinion · Devil's advocate
Fact-check-o-meter
United Therapeutics' filings back its trial claims, but the upbeat release language sits next to falling Tyvaso sales
The trial figures in the 10-Q match the company's public statements, and both big phase 3 programs were randomized and double-blind per ClinicalTrials.gov. The gaps are tonal: the Q2 release opens with the 2% revenue decline, and the executive quotes that follow stress the two NDA filings, multi-billion-dollar catalysts and record Tyvaso DPI demand, while the filing says competitive therapies negatively impacted sales. The Liquidia settlement filed in October is the biggest legal change since the 10-Q.
Press release vs filing · weight medium
'Record' Tyvaso DPI demand, but Tyvaso and total revenue fell
The company said: "Tyvaso DPI exited the second quarter at record levels of starts, referrals, commercial patients, and total patients, reflecting strong underlying demand," source
The record says: The 10-Q attributes a Nebulized Tyvaso drop to a "decrease in U.S. quantities sold of $37.6 million" and adds: "We believe the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin for the three and six months ended June 30, 2026." source
Our view: The release itself reports the 2% revenue decline and repeats the competition language, so nothing is hidden (total Tyvaso revenue fell 4% to $452.6 million, per the release). But the release opens with the revenue decline, and the two executive quotes that follow stress the NDA filings and record Tyvaso DPI starts, while U.S. quantities sold fell for Nebulized Tyvaso and Remodulin.
Science · weight medium
IPF results are strong on lung function, but survival did not reach significance
The company said: "two potentially transformative, multi-billion-dollar catalysts that could significantly enhance our growth profile." source
The record says: The 10-Q reports FVC gains of 130.1 mL in TETON-1 and 95.6 mL in TETON-2, then states: "Overall survival at week 52 trended in favor of Nebulized Tyvaso but did not meet statistical significance." ClinicalTrials.gov lists TETON-1 as masked ("QUADRUPLE") with 598 participants and a single primary outcome, "Change in Absolute FVC from Baseline to Week 52". source
Our view: The design is sound: randomized, double-blind and placebo-controlled with a clear lung-function endpoint. The two trials differed by about 35 mL, and FVC is a surrogate for how patients live and survive. Regulators may weigh the survival trend, and the 'multi-billion' figure is the company's own forecast.
Science · weight medium
Ralinepag's win rests on a composite clinical worsening endpoint
The company said: "The study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55 percent compared with placebo in patients with PAH (hazard ratio 0.45, p<0.0001)." source
The record says: The ClinicalTrials.gov primary outcome is "Time from randomization to the first adjudicated protocol-defined clinical worsening event", defined as "death, nonelective hospital admission for worsening PAH", prostacyclin initiation, "disease progression", or "unsatisfactory long-term clinical response". The trial is randomized and quadruple-masked with 687 participants. source
Our view: Composite endpoints can be driven by the softer components, and neither source here splits the 55% reduction by component. A breakdown by component and the 6-minute walk result would show how much the composite rests on its softer components.
Legal and disclosure record · weight medium
Liquidia and Sandoz matters settled in October; releases take effect after payments, a label change and dismissals
The record says: The October 14 8-K says "On September 30, 2026, the District Court held Liquidia liable for infringement of claims 1 and 14 of the '327 patent" in the U.S. District Court for the District of Delaware. Under the October 13 settlement, "Liquidia will pay to UT an aggregate of $330.4 million" and UT will make a "$10.0 million payment" to Liquidia to settle the RareGen and Sandoz matter, after the Third Circuit on October 7 "vacating the November 1, 2024 judgment and damages award". No securities litigation or enforcement action is disclosed in the 10-Q; its legal note lists a payor class action under RICO and antitrust law in the Southern District of Florida. source
Our view: The August results release did not mention Liquidia, and the 10-Q still described the cases as pending. The settlement removes the largest dispute and adds cash, but it depends on Liquidia making payments and on FDA approving a label change.
Stock chart
SEC filings and registration
- SEC name
- UNITED THERAPEUTICS Corp
- CIK
- 1082554
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- UTHR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 1000 SPRING ST, SILVER SPRING, MD, 20910
- Phone
- 3016089292
- Shares outstanding
- 42,890,692 as of 2026-07-29 (10-Q filed 2026-08-05)
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction